Home › Funds › BNY Mellon › BNY Mellon Small/Mid Cap Growth Fund
Fund family: BNY Mellon · Filed by BNY Mellon Investment Funds I (CIK 799295) · SEC series S000011499
Share classes and tickers: DBMAX (C000075527), DBMCX (C000075528), DBMYX (C000130460), DBMZX (C000193013), SDSCX (C000031760)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 542 with, 6 against, 0 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 4 FOR, 3 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as BNY Mellon’s manager page (141,760 ballot items across 60 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | BNY Mellon | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 90.9% | 519 | 93.1% | 117,600 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 1.8% | 1,473 |
Each ballot item this fund voted is set against the votes of the other BNY Mellon funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most BNY Mellon funds on 12 items (2.5% of the 488 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most BNY Mellon funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Cytokinetics, Incorporated | 2026-05-27 | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. | Against | FOR — 6 of 8 BNY Mellon funds | Against | Approved, 97.2% support |
| Patrick Industries, Inc. | 2026-05-14 | To approve, in an advisory and non-binding vote, the compensation of the Company's named executive officers for fiscal year 2025. | Against | FOR — 6 of 8 BNY Mellon funds | Against | Passed (calculated), 97.3% support |
| Pool Corporation | 2026-04-29 | Ratification of the retention of Ernst & Young LLP, certified public accountants, as our independent registered public accounting firm for the 2026 fiscal year. | Against | FOR — 4 of 5 BNY Mellon funds | Against | Approved, 96.5% support |
| SiTime Corporation | 2026-05-29 | To approve, on an advisory basis, the compensation of SiTime's named executive officers as disclosed in SiTime's proxy statement. | Against | FOR — 5 of 7 BNY Mellon funds | Against | Approved, 82.1% support |
| Bio-Techne Corporation | 2025-10-30 | Approve, on an advisory basis, the compensation of our executive officers. | Against | FOR — 6 of 10 BNY Mellon funds | Against | Approved, 72.1% support |
| The Timken Company | 2026-05-08 | Approval, on an advisory basis, of our named executive officer compensation. | For | AGAINST — 5 of 8 BNY Mellon funds | For | Approved, 74.6% support |
| Bio-Techne Corporation | 2025-10-30 | Elections of Directors: Alpna Seth | Against | FOR — 4 of 6 BNY Mellon funds | Against | Elected, 95.8% support |
| MKS Inc. | 2026-05-11 | The approval, on an advisory basis, of executive compensation. | Against | FOR — 5 of 9 BNY Mellon funds | Against | — |
| Onto Innovation Inc. | 2026-05-20 | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the proxy statement; and | Against | FOR — 5 of 9 BNY Mellon funds | Against | Approved, 97.1% support |
| GeneDx Holdings Corp. | 2026-06-18 | Approval, on a non-binding advisory basis, the compensation of our named executive officers. | Against | FOR — 4 of 7 BNY Mellon funds | Against | Passed (calculated), 93.9% support |
| Patrick Industries, Inc. | 2026-05-14 | To elect nine directors to the Board of Directors to serve until the 2027 Annual Meeting of Shareholders: John A. Forbes | Withhold | FOR — 3 of 5 BNY Mellon funds | Against | Elected, 92.6% support |
| Patrick Industries, Inc. | 2026-05-14 | To elect nine directors to the Board of Directors to serve until the 2027 Annual Meeting of Shareholders: Joseph M. Cerulli | Withhold | FOR — 3 of 5 BNY Mellon funds | Against | Elected, 83.6% support |
Download all 12 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 95.8% of this fund’s 548 such votes could be given a sector; the other 23 (4.2%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Industrials | 169 | 5 | 3.0% |
| Health Care | 138 | 0 | 0.0% |
| Consumer Discretionary | 110 | 1 | 0.9% |
| Technology | 61 | 0 | 0.0% |
| Energy | 27 | 0 | 0.0% |
| Finance | 13 | 0 | 0.0% |
| Basic Materials | 7 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 354 | 0 |
| Audit-related | 66 | 0 |
| Say-on-Pay | 64 | 0 |
| Compensation | 25 | 0 |
| Corporate Governance | 24 | 4 |
| Capital Structure | 13 | 0 |
| Extraordinary Transactions | 6 | 1 |
| Shareholder Rights and Defenses | 4 | 0 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Casey's General Stores, Inc. | September 3, 2025 | $43M | 15 | 1 |
| Repligen Corporation | May 14, 2026 | $36M | 11 | 0 |
| Guardant Health, Inc. | June 17, 2026 | $29M | 5 | 0 |
| Bio-Techne Corporation | October 30, 2025 | $28M | 12 | 0 |
| SiTime Corporation | May 29, 2026 | $23M | 5 | 0 |
| Flowserve Corporation | May 14, 2026 | $22M | 12 | 1 |
| Roper Technologies, Inc. | May 19, 2026 | $21M | 14 | 1 |
| Herc Holdings Inc. | May 14, 2026 | $20M | 10 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| September 3, 2025 | Casey's General Stores, Inc. | Shareholder proposal regarding Scope 3 greenhouse gas reduction targets. Shareholder proposal | Against | For |
| May 14, 2026 | Flowserve Corporation | Shareholder Proposal requesting an annual advisory shareholder vote regarding Flowserve stock repurchases. Shareholder proposal | Against | For |
| May 19, 2026 | Roper Technologies, Inc. | Shareholder proposal regarding a strategic review of a proposed spin-off of the Application Software and Network Software segments. Shareholder proposal | Against | For |
| May 8, 2026 | The Timken Company | Consideration of a shareholder proposal asking our Board of Directors to take the steps necessary to amend the appropriate Company governing documents to give the owners of a combined 10% of our outstanding common stock the power to call a special shareholder meeting or the owners of the lowest percentage of shareholders, as governed by state law, the power to call a special shareholder meeting. Shareholder proposal | For | Against |
| May 11, 2026 | MKS Inc. | A shareholder proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 10%, if properly presented at the meeting. Shareholder proposal | For | Against |
| May 6, 2026 | Entegris, Inc. | Stockholder Proposal: Providing stockholders the right to call special meetings of stockholders. Shareholder proposal | For | Against |
557 ballot items at 66 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, BNY Mellon Small/Mid Cap Growth Fund (DBMAX) voted at 66 shareholder meetings of 65 companies, on 557 ballot items in all. Where management made a recommendation, the fund followed it on 98.9% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals less often than BNY Mellon's funds as a whole (90.9% against 93.1%). It voted differently from most BNY Mellon funds on 12 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BNY Mellon’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.